Subtype
Ovarian Carcinoma
CI-CAN-00003517Explore in graph →
270 active trials2 approved drugs24 evidence items
- NCIt
- C4908
- DOID
- 2152
- DOID
- 4001
- MeSH
- D000077216
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003517Explore in graph →
Clinical trials
895 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | completed | Phase 3 | 349 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT04902144 | Clinical Outcomes for Offering Genetic Testing in a Tiered Approach | completed | N/A | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT01847274 |
| A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer |
| completed |
| Phase 3 |
| 596 |
| Tesaro, Inc.INDUSTRY |
| 15 |
| Jun 2, 2023 |
| clinicaltrials |
| NCT02898207 | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 26, 2023 | clinicaltrials |
| NCT00538031 | Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 52 | City of Hope Medical CenterOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03507452 | First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | completed | Phase 1 | 36 | BayerINDUSTRY | 5 | Mar 20, 2023 | clinicaltrials |
| NCT03756818 | TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT02166905 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | completed | Phase 1 / Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT02025985 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies(SIGN) | completed | Phase 2 | 116 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jan 26, 2023 | clinicaltrials |
| NCT04753216 | Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 3 | Northwestern UniversityOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT02489058 | A Study of Long-Term Responders on Olaparib(OLALA) | completed | — | 118 | University Health Network, TorontoOTHER | 5 | Jan 10, 2023 | clinicaltrials |
| NCT03398655 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)(OVAL) | completed | Phase 3 | 408 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 5 | Jan 10, 2023 | clinicaltrials |
| NCT02595281 | HE4 as a Relapse Biomarker in Ovarian Cancers(PRONOV4IR) | completed | N/A | 90 | Institut de Cancérologie de LorraineOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT02013492 | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery | completed | Early Phase 1 | 1 | William CarsonOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT01097746 | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 2 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT00623831 | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen | completed | Phase 1 | 17 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT00616941 | Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 28 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03857087 | 68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer | completed | — | 7 | University of California, San FranciscoOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03106987 | A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.(OReO) | completed | Phase 3 | 220 | AstraZenecaINDUSTRY | 11 | Oct 7, 2022 | clinicaltrials |
| NCT02518256 | Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity(LUDOC II) | completed | N/A | 270 | Medical University of ViennaOTHER | 4 | Sep 6, 2022 | clinicaltrials |
| NCT02039388 | Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma(LUSTIC) | completed | N/A | 701 | Medical University of ViennaOTHER | 8 | Sep 2, 2022 | clinicaltrials |
| NCT04823871 | Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing(EHUD) | completed | N/A | 406 | Paul Speiser, Prof.MD,OTHER | 4 | Sep 2, 2022 | clinicaltrials |
| NCT01673217 | Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT03029598 | Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT02952521 | Ovarian Tumor Biopsies to Study Response to Treatments | completed | — | 5 | University Health Network, TorontoOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT02107937 | Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma | completed | Phase 2 | 136 | SOTIO a.s.INDUSTRY | 2 | May 4, 2022 | clinicaltrials |
| NCT03372720 | Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors | completed | N/A | 19 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT00181701 | Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | completed | Phase 2 | 46 | Massachusetts General HospitalOTHER | 0 | Apr 14, 2022 | clinicaltrials |
| NCT00853307 | MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma | completed | Phase 2 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 8, 2022 | clinicaltrials |
| NCT02324439 | Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission | completed | Phase 1 | 15 | Southern Illinois UniversityOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT04651920 | A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer | completed | — | 240 | Lei LiOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT02889900 | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer(CONCERTO) | completed | Phase 2 | 62 | AstraZenecaINDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT02316834 | Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(POSITION) | completed | Early Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT00096200 | Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT00886691 | Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 150 | GOG FoundationNETWORK | 1 | Feb 4, 2022 | clinicaltrials |
| NCT05188781 | Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer | completed | — | 34 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT02315469 | Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery | completed | — | 190 | NRG OncologyOTHER | 2 | Nov 24, 2021 | clinicaltrials |
| NCT02657928 | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | completed | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT00888615 | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 58 | GOG FoundationNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT00989651 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 431 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01720173 | Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 30 | Gynecologic Oncology GroupNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01853644 | Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer(TIVO) | completed | Phase 2 | 31 | Northwestern UniversityOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02853318 | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03685695 | Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT04537702 | Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients | completed | N/A | 64 | Duke UniversityOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04546373 | Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer | completed | — | 316 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Aug 5, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Jun 9, 2023source: clinicaltrials